VACCINES AGAINST DENGUE VIRUS

Team Members

Dr. Nikole Warner

Nikhet Chowdhury

Susan Core

We are using virus-like particles (VLPs) derived from small RNA bacteriophages as antigen-display platforms for dengue virus vaccines.  We identify antigens of interest that are important for dengue virus infection and pathogenesis, display them on VLPs using a variety of molecular biology techniques, and then test them for their immunogenicity and ability to elicit antibodies that can block dengue virus infection or key functions of the antigens.

 
  • Twitter
  • LinkedIn

©2020 by Kathryn Frietze, PhD
Albuquerque, NM USA